Product
AAV2-hRPE65v2
Aliases
AAV2-hRPE65v2,voretigene neparvovec-rzyl, gene therapy vector, voretigene neparvovec, Voretigene Neparvovec-rzyl
Name
LUXTURNA
INN Name
voretigene neparvovec-rzyl
FDA Approved
Yes
2 clinical trials
1 organization
2 indications
1 document
Indication
Leber Congenital AmaurosisClinical trial
A Long-Term Follow-Up Study in Subjects Who Received an Adenovirus-Associated Viral Vector Serotype 2 Containing the Human RPE65 Gene (AAV2-hRPE65v2, Voretigene Neparvovec-rzyl) Administered Via Subretinal InjectionStatus: Active (not recruiting), Estimated PCD: 2030-03-01
Clinical trial
A Post-Authorization, Multicenter, Longitudinal, Observational Safety Registry Study for Patients Treated With Voretigene Neparvovec in USStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Document
DailyMed Label: LUXTURNAOrganization
Spark Therapeutics, Inc.